Open Access


Read more
image01

Online Manuscript Submission


Read more
image01

Submitted Manuscript Trail


Read more
image01

Online Payment


Read more
image01

Online Subscription


Read more
image01

Email Alert



Read more
image01

Original Research Article | OPEN ACCESS

Comparison of classical, stealth and super-stealth liposomes for intravenous delivery of lumefantrine: Formulation, characterization and pharmacodynamic study

Ebele Onuigbo1 , Anthony Attama2, Elena Canato3, Gianfranco Pasut3

1Department of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka; 2Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka 410001, Nigeria; 3Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua 35131, Italy.

For correspondence:-  Ebele Onuigbo   Email: ebele.onuigbo@unn.edu.ng   Tel:+2348062995712

Accepted: 19 October 2020        Published: 30 November 2020

Citation: Onuigbo E, Attama A, Canato E, Pasut G. Comparison of classical, stealth and super-stealth liposomes for intravenous delivery of lumefantrine: Formulation, characterization and pharmacodynamic study. Trop J Pharm Res 2020; 19(11):2247-2253 doi: 10.4314/tjpr.v19i11.1

© 2020 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To develop and compare classical liposomes (CL), stealth liposomes (SL) and super-stealth liposomes (SSL) encapsulating lumefantrine for intravenous administration.
Method: CL, SL or SSL were prepared by thin-layer evaporation method and evaluated for particle size, polydispersity index (PdI), encapsulation efficiency and short-term stability. Pharmacodynamic study using mice infected with Plasmodium berghei was also carried out.
Results: The particle sizes (nm) and PDI of the liposomes were: CL (248 ± 44.89; 0.78 ± 0.02), SL (235.8 ± 45.18; 0.39 ± 0.06) and SSL (238.2 ± 23.0; 0.24 ± 0.04). Encapsulation efficiency was highest in SSL (66 %), followed by SL (44.4 %) and then by CL (42.5 %). SSL was the most stable after 72 h of storage. In vivo, lumefantrine produced significant reduction in parasitaemia after 7 days (p < 0.05) by SSL (68.3 ± 8.9 %) followed by CL (55.8 ± 15.2 %) and then SL (53.4 ± 14.9 %).
Conclusion: SSL formulation of lumefantrine exhibits good physicochemical and pharmacodynamic potentials and should be further investigated in future studies for the treatment of malaria.

Keywords: Drug delivery, Classical liposomes, Stealth liposomes, Super-stealth liposomes, Lumefantrine, Malaria

Impact Factor
Thompson Reuters (ISI): 0.6 (2023)
H-5 index (Google Scholar): 49 (2023)

Article Tools

Share this article with



Article status: Free
Fulltext in PDF
Similar articles in Google
Similar article in this Journal:

Archives

2024; 23: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10
2023; 22: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2022; 21: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2021; 20: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2020; 19: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2019; 18: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2018; 17: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2017; 16: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2016; 15: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2015; 14: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2014; 13: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2013; 12: 
1,   2,   3,   4,   5,   6
2012; 11: 
1,   2,   3,   4,   5,   6
2011; 10: 
1,   2,   3,   4,   5,   6
2010; 9: 
1,   2,   3,   4,   5,   6
2009; 8: 
1,   2,   3,   4,   5,   6
2008; 7: 
1,   2,   3,   4
2007; 6: 
1,   2,   3,   4
2006; 5: 
1,   2
2005; 4: 
1,   2
2004; 3: 
1
2003; 2: 
1,   2
2002; 1: 
1,   2

News Updates